Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > IR responce

<< Previous

Bullboard Posts

Next >>

Comment by yessimon Feb 11, 2021 1:07pm

128 Views

Post# 32542045

RE:RE:IR responce

Look i have limited knowledge on such things, but if china approves .....why would they give 100 mil. in milstone payments.
If someone can explain why Im wrong please tell me.
my first buy in was X-mas 2017 and averaged up right up to last summer.....selling none along the way. Not trying to sound negative just seemed like a valid thought.
Thx.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"